# Accelerated Enrollment Solutions

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accelerated-enrollment-solutions

- Industry: Healthcare IT
- Headquarters: Horsham, US
- Website: www.acurian.com
- Total disclosed funding: $27M
- Latest round: Series B (Mar 28, 2001)
- Investors on record: 6

## About

Accelerated Enrollment Solutions specializes in clinical trial patient recruitment, providing essential services to ensure effective participation by patients and volunteers in research studies.Accelerated Enrollment Solutions, headquartered in Horsham, US, focuses on enhancing clinical trial participation. Founded in 1998, the company has successfully completed four deals, with its most recent being a Series B funding round in August 2013 led by EuclidSR Partners, raising USD 27.00 mn. The company was acquired by Pharmaceutical Product Development, Inc., a portfolio company of Carlyle Group and Hellman & Friedman, although specific financial details of the acquisition were not disclosed.Accelerated Enrollment Solutions facilitates participation in clinical trials by offering services such as patient recruitment, study planning, patient identification, pre-screening, and integrated site services. Their extensive database of over 20 million identified patients allows for efficient matching of participants to trials, servicing a diverse clientele including pharmaceutical companies, CROs, and healthcare institutions across North America, Europe, and parts of Asia.Accelerated Enrollment Solutions generates revenue through service agreements with biopharmaceutical and biotechnology companies, focusing on B2B transactions. Fees are charged for recruitment services, which encompass study planning and trial logistics management. Their extensive patient database and specialized teams for early-phase trials create a robust value proposition for sponsors during clinical trials, although specific pricing details are not publicly available.In the coming years, Accelerated Enrollment Solutions aims to expand its market presence by launching new products designed to streamline clinical trial processes and enhance patient engagement. The company is targeting growth in specific geographical regions, including Europe and Asia, with plans to establish a more significant footprint by 2025. The proceeds from the USD 27.00 mn raised during the Series B funding round will support these initiatives, enhancing their operational capabilities and improving recruitment efficiencies.

## Funding rounds

- Series B, Mar 28, 2001, $27M — EuclidSR Partners, CDPQ, ProQuest Investments, JP Morgan Asset Management, Merck Capital Ventures, Flatirons Partners

## Investors

- EuclidSR Partners (https://capitalatlas.ai/funds/euclidsr-partners) — Series B
- CDPQ — Series B
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series B
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series B
- Merck Capital Ventures (https://capitalatlas.ai/funds/merck-capital-ventures) — Series B
- Flatirons Partners (https://capitalatlas.ai/funds/flatirons-partners) — Series B